{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:57:40Z","timestamp":1792807060038,"version":"4.5.0"},"reference-count":174,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) represents the hepatic manifestation of systemic metabolic dysfunction and has emerged as one of the leading causes of chronic liver disease worldwide. Its pathogenesis is complex and multifactorial, involving insulin resistance, altered lipid metabolism, mitochondrial dysfunction, oxidative stress, and chronic low-grade inflammation. Beyond these classical mechanisms, growing evidence highlights the central role of modifiable lifestyle-related factors, including chronic positive energy balance, high intake of fructose and saturated fats, ultra-processed foods, physical inactivity, sleep disruption, and environmental exposures such as endocrine-disrupting chemicals and air pollution, which have been associated with the activation of lipogenic and proinflammatory pathways in preclinical and observational studies. Conversely, protective dietary patterns, particularly the Mediterranean diet, together with regular physical activity, exert hepatoprotective metabolic and anti-inflammatory effects. An extensive literature search was conducted across the PubMed, Scopus, Cochrane Library, and Embase databases, covering publications through June 2026. The review was conducted following the SANRA recommendations for narrative reviews. The inclusion criteria encompassed clinical trials, systematic reviews, meta-analyses, and international clinical practice guidelines. This review provides an integrated framework by linking in a single interpretative model the classical pathogenic pathways with emerging dietary, behavioral, and environmental determinants and with systemic interorgan communication networks involving hepatokines, adipokines, and myokines. Understanding MASLD as a multisystemic metabolic disease driven by multiple determinants has critical implications for the development of targeted preventive and therapeutic strategies aimed at reducing its global burden and prevalence.<\/jats:p>","DOI":"10.3390\/nu18142316","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:05:07Z","timestamp":1784163907000},"page":"2316","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): From Steatosis to Systemic Metabolic Failure: Classical Pathophysiology, Emerging Systemic Mechanisms and Modifiable Lifestyle Determinants"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5938-0850","authenticated-orcid":false,"given":"Stefania","family":"Capuccio","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy"},{"name":"Department of Medicine and Surgery, \u201cKore\u201d University of Enna, 94100 Enna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Cocuzza","sequence":"additional","affiliation":[{"name":"Liver Unit, National and High-Specialization Hospital Trust Garibaldi-Nesima, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia Letizia","family":"Di Marco","sequence":"additional","affiliation":[{"name":"Liver Unit, National and High-Specialization Hospital Trust Garibaldi-Nesima, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4483-3365","authenticated-orcid":false,"given":"Alessandra","family":"Scamporrino","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, \u201cKore\u201d University of Enna, 94100 Enna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1781-0902","authenticated-orcid":false,"given":"Salvatore","family":"Piro","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3650-5541","authenticated-orcid":false,"given":"Maurizio","family":"Russello","sequence":"additional","affiliation":[{"name":"Liver Unit, National and High-Specialization Hospital Trust Garibaldi-Nesima, 95122 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2023.11.005","article-title":"Natural history of metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Lekakis","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Soto, A., Spongberg, C., Martinino, A., and Giovinazzo, F. (2024). Exploring the multifaceted landscape of MASLD: A comprehensive synthesis of recent studies, from pathophysiology to organoids and beyond. Biomedicines, 12.","DOI":"10.3390\/biomedicines12020397"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Yang, B., Lu, L., Zhou, D., Fan, W., Barbier-Torres, L., Steggerda, J., Yang, H., and Yang, X. (2022). Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1007944"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Gastaldelli, A., Scoditti, E., and Macedo, M.P. (2026). Metabolic drivers of MASLD and MASH: From hormonal imbalance to fibrosis. Diabetologia, Epub ahead of print.","DOI":"10.1007\/s00125-026-06774-7"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kong, Y., Chen, H., Chen, Y., and Wang, C. (2026). The application of artificial intelligence in the intersection of metabolic dysfunction-associated steatotic liver disease and cardiovascular diseases. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1788249"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","article-title":"Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009\u20132019","volume":"75","author":"Golabi","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic Dysfunction\u2013Associated Steatotic Liver Disease (MASLD) in people with diabetes: The need for screening and early intervention. A consensus report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic Dysfunction\u2013Associated Steatotic Liver Disease","volume":"393","author":"Targher","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic Dysfunction\u2013Associated Steatotic Liver Disease in adults: A review","volume":"335","author":"Tilg","year":"2026","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/LVT.0000000000000688","article-title":"Steatotic liver disease is the dominant indication for liver transplantation in both Europe and the United States: Trends and outcomes in the past 2 decades","volume":"32","author":"Younossi","year":"2026","journal-title":"Liver Transpl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical Bayesian approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: A systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/hep.32112","article-title":"Hepatocyte-specific deletion of adipose triglyceride lipase (adipose triglyceride lipase\/patatin-like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice","volume":"75","author":"Fuchs","year":"2022","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Qu, W., Ma, T., Cai, J., Zhang, X., Zhang, P., She, Z., Wan, F., and Li, H. (2021). Liver fibrosis and MAFLD: From molecular aspects to novel pharmacological strategies. Front. Med., 8.","DOI":"10.3389\/fmed.2021.761538"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e49882","DOI":"10.7554\/eLife.49882","article-title":"Obesity-linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease","volume":"8","author":"Helsley","year":"2019","journal-title":"eLife"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: Heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jhep.2024.10.048","article-title":"PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by inhibiting ATGL-mediated triglyceride hydrolysis","volume":"82","author":"Wang","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Juanola, O., Mart\u00ednez-L\u00f3pez, S., Franc\u00e9s, R., and G\u00f3mez-Hurtado, I. (2021). Non-alcoholic fatty liver disease: Metabolic, genetic, epigenetic and environmental risk factors. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18105227"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Mantovani, A., Taverna, A., Cappelli, D., Beatrice, G., Csermely, A., Sani, E., Byrne, C.D., and Targher, G. (2022). Long-term adverse effect of liver stiffness on glycaemic control in type 2 diabetic patients with nonalcoholic fatty liver disease: A pilot study. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012481"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"119053","DOI":"10.1016\/j.atherosclerosis.2024.119053","article-title":"Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"400","author":"Maccali","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9547613","DOI":"10.1155\/2018\/9547613","article-title":"Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease","volume":"2018","author":"Masarone","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00204-024-03696-4","article-title":"Several lines of antioxidant defense against oxidative stress: Antioxidant enzymes, nanomaterials with multiple enzyme-mimicking activities, and low-molecular-weight antioxidants","volume":"98","author":"Jomova","year":"2024","journal-title":"Arch. Toxicol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jhep.2025.08.017","article-title":"Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD","volume":"84","author":"Zhou","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/HEP.0000000000001333","article-title":"Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data","volume":"83","author":"Ng","year":"2026","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Rubio, A., Juli\u00e1n, M.T., Valassi, E., Alonso, N., and Puig-Domingo, M. (2026). Unveiling the role of aldosterone in metabolic dysfunction-associated steatotic liver disease. Rev. Endocr. Metab. Disord., Epub ahead of print.","DOI":"10.1007\/s11154-026-10056-3"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.nutres.2025.03.004","article-title":"High salt diet causally increases metabolic dysfunction-associated steatotic liver disease risk: A bidirectional Mendelian randomization study","volume":"136","author":"Liu","year":"2025","journal-title":"Nutr. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/s41374-017-0018-z","article-title":"Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats","volume":"98","author":"Kwanten","year":"2018","journal-title":"Lab. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Milosevic, I., Vujovic, A., Barac, A., Djelic, M., Korac, M., Radovanovic Spurnic, A., Gmizic, I., Stevanovic, O., Djordjevic, V., and Lekic, N. (2019). Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: A review of the literature. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020395"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut\u2013liver axis and the intersection with the microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12020-022-03279-2","article-title":"Correlation between thyroid function, sensitivity to thyroid hormones and metabolic dysfunction-associated fatty liver disease in euthyroid subjects with newly diagnosed type 2 diabetes","volume":"80","author":"Zhang","year":"2022","journal-title":"Endocrine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"103034","DOI":"10.1016\/j.dsx.2024.103034","article-title":"Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom","volume":"18","author":"Kuchay","year":"2024","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/apt.17930","article-title":"Pathogenesis of MASLD and MASH\u2014Role of insulin resistance and lipotoxicity","volume":"59","author":"Bansal","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_36","first-page":"OC01","article-title":"Metabolic profile of lean\/non-obese NAFLD (Non Alcoholic Fatty Liver Disease) subjects","volume":"15","author":"Jaiswal","year":"2021","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s42255-021-00493-6","article-title":"Lipolysis: Cellular mechanisms for lipid mobilization from fat stores","volume":"3","author":"Grabner","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Rao, G., Peng, X., Li, X., An, K., He, H., Fu, X., Li, S., and An, Z. (2023). Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: From mechanism to the clinic. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1294267"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.gastro.2018.06.031","article-title":"Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis","volume":"155","author":"Musso","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1111\/liv.15059","article-title":"The role of hepatic lipid composition in obesity-related metabolic disease","volume":"41","author":"Willis","year":"2021","journal-title":"Liver Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The role of cholesterol in the pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0006-291X(75)90482-9","article-title":"Delineation of the intimate details of the backbone conformation of pyridine nucleotide coenzymes in aqueous solution","volume":"66","author":"Bose","year":"1975","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cmet.2012.04.004","article-title":"Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease","volume":"15","author":"Min","year":"2012","journal-title":"Cell Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2010.01.003","article-title":"Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis","volume":"52","author":"Akazawa","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-nutr-071812-161230","article-title":"Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease","volume":"33","author":"Scorletti","year":"2013","journal-title":"Annu. Rev. Nutr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.plefa.2009.05.020","article-title":"The essentiality of arachidonic acid and docosahexaenoic acid","volume":"81","author":"Le","year":"2009","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"31587","DOI":"10.1038\/srep31587","article-title":"Hepatic and serum lipid signatures specific to nonalcoholic steatohepatitis in murine models","volume":"6","author":"Chiappini","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"G77","DOI":"10.1152\/ajpgi.00301.2011","article-title":"Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis","volume":"302","author":"Kakisaka","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1478-3231.2007.01475.x","article-title":"Sphingolipid signalling and liver diseases","volume":"27","year":"2007","journal-title":"Liver Int."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Wang, F. (2026). Targeting ferroptosis to halt MASLD and MASH. Trends Endocrinol. Metab., 37.","DOI":"10.1016\/j.tem.2026.01.007"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"8122","DOI":"10.1074\/jbc.270.14.8122","article-title":"Expression, characterization, and crystallization of the catalytic core of the human insulin receptor protein-tyrosine kinase domain","volume":"270","author":"Wei","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_54","first-page":"e14607","article-title":"Mechanisms of muscle insulin resistance and the cross-talk with liver and adipose tissue","volume":"8","author":"Nayak","year":"2020","journal-title":"Physiol. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.31806","article-title":"Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease","volume":"74","author":"Alexopoulos","year":"2021","journal-title":"Hepatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41575-025-01045-z","article-title":"Metabolic dysfunction-associated steatotic liver disease: A condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment","volume":"22","author":"Byrne","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Rajapaksha, I.G., Gunarathne, L.S., Angus, P.W., and Herath, C.B. (2021). Update on new aspects of the renin-angiotensin system in hepatic fibrosis and portal hypertension: Implications for novel therapeutic options. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040702"},{"key":"ref_58","first-page":"1","article-title":"Bidirectional association between hypertension and NAFLD: A systematic review and meta-analysis of observational studies","volume":"2022","author":"Li","year":"2022","journal-title":"Int. J. Endocrinol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cmet.2011.11.004","article-title":"Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease","volume":"14","author":"Sunny","year":"2011","journal-title":"Cell Metab."},{"key":"ref_60","first-page":"1121","article-title":"CYP4A11 is involved in the development of nonalcoholic fatty liver disease via ROS-induced lipid peroxidation and inflammation","volume":"45","author":"Gao","year":"2020","journal-title":"Int. J. Mol. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00424-018-2195-z","article-title":"Catalase and nonalcoholic fatty liver disease","volume":"470","author":"Shin","year":"2018","journal-title":"Pflug. Arch. Eur. J. Physiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41580-023-00645-4","article-title":"Understanding mechanisms of antioxidant action in health and disease","volume":"25","author":"Halliwell","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"101950","DOI":"10.1016\/j.redox.2021.101950","article-title":"The diverse functionality of NQO1 and its roles in redox control","volume":"41","author":"Ross","year":"2021","journal-title":"Redox Biol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Arroyave-Ospina, J.C., Wu, Z., Geng, Y., and Moshage, H. (2021). Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: Implications for prevention and therapy. Antioxidants, 10.","DOI":"10.3390\/antiox10020174"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jhep.2022.03.017","article-title":"Endoplasmic reticulum-mitochondria miscommunication is an early and causal trigger of hepatic insulin resistance and steatosis","volume":"77","author":"Beaulant","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"The Integrative HMP (iHMP) Research Network Consortium, Proctor, L.M., Creasy, H.H., Fettweis, J.M., Lloyd-Price, J., Mahurkar, A., Zhou, W., Buck, G.A., Snyder, M.P., and Strauss, J.F. (2019). The Integrative Human Microbiome Project. Nature, 569, 641\u2013648.","DOI":"10.1038\/s41586-019-1238-8"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","article-title":"Altered profile of human gut microbiome is associated with cirrhosis and its complications","volume":"60","author":"Bajaj","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4291\/wjgp.v6.i4.110","article-title":"New-found link between microbiota and obesity","volume":"6","author":"Chakraborti","year":"2015","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/gut.2009.190801","article-title":"Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease","volume":"59","author":"Dongiovanni","year":"2010","journal-title":"Gut"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/hep4.1822","article-title":"TM6SF2: A novel genetic player in nonalcoholic fatty liver and cardiovascular disease","volume":"6","author":"Luo","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/460190","article-title":"Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis","volume":"2015","author":"Dongiovanni","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41574-021-00507-z","article-title":"Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus","volume":"17","author":"Ferguson","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s42649-023-00089-2","article-title":"Therapeutic treatments for diabetes mellitus-induced liver injury by regulating oxidative stress and inflammation","volume":"53","author":"Bae","year":"2023","journal-title":"Appl. Microsc."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1074\/jbc.M115.701094","article-title":"Differential roles of cell death-inducing DNA fragmentation factor-\u03b1-like effector (CIDE) proteins in promoting lipid droplet fusion and growth in subpopulations of hepatocytes","volume":"291","author":"Xu","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"852","DOI":"10.7150\/ijbs.19370","article-title":"Emerging roles of SIRT1 in fatty liver diseases","volume":"13","author":"Ding","year":"2017","journal-title":"Int. J. Biol. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1530\/EC-21-0353","article-title":"IGFBP-2 as a biomarker in NAFLD improves hepatic steatosis: An integrated bioinformatics and experimental study","volume":"10","author":"Chen","year":"2021","journal-title":"Endocr. Connect."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13148-015-0056-6","article-title":"Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease","volume":"7","author":"Zeybel","year":"2015","journal-title":"Clin. Epigenet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1053\/j.gastro.2013.07.047","article-title":"Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease","volume":"145","author":"Murphy","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e13038","DOI":"10.1002\/jgh3.13038","article-title":"Low thyroid function is associated with metabolic dysfunction-associated steatotic liver disease","volume":"8","author":"Wang","year":"2024","journal-title":"JGH Open"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e25738","DOI":"10.1097\/MD.0000000000025738","article-title":"The relationship between non-alcoholic fatty liver disease and hypothyroidism: A systematic review and meta-analysis","volume":"100","author":"Zeng","year":"2021","journal-title":"Medicine"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jhep.2012.02.027","article-title":"Non-alcoholic fatty liver disease across the spectrum of hypothyroidism","volume":"57","author":"Chung","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_84","first-page":"e70431","article-title":"Thyroid-liver axis: The role of thyroid dysfunction in the pathogenesis and progression of MASLD: A comprehensive review","volume":"45","author":"Capuccio","year":"2025","journal-title":"Liver Int."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1530\/EC-18-0499","article-title":"Reduced expression of thyroid hormone receptor \u03b2 in human nonalcoholic steatohepatitis","volume":"7","author":"Krause","year":"2018","journal-title":"Endocr. Connect."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41418-024-01348-9","article-title":"Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Peleman","year":"2024","journal-title":"Cell Death Differ."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e180310","DOI":"10.1172\/JCI180310","article-title":"The senescence-associated secretome of Hedgehog-deficient hepatocytes drives MASLD progression","volume":"134","author":"Jun","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Chen, J., Jian, L., Guo, Y., Tang, C., Huang, Z., and Gao, J. (2024). Liver cell mitophagy in metabolic dysfunction-associated steatotic liver disease and liver fibrosis. Antioxidants, 13.","DOI":"10.3390\/antiox13060729"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e70155","DOI":"10.1002\/cph4.70155","article-title":"The mitochondrial-autophagy axis in MASLD: Mechanisms, crosstalk, and therapeutic targets","volume":"16","author":"Bhaduri","year":"2026","journal-title":"Compr. Physiol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Lei, Y., Liu, M., and Tao, X. (2026). Extracellular vesicles: Orchestrators of intrahepatic and systemic crosstalk in metabolic dysfunction-associated steatotic liver disease. Pharmaceutics, 18.","DOI":"10.3390\/pharmaceutics18010116"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"108259","DOI":"10.4254\/wjh.v17.i9.108259","article-title":"Extracellular vesicles in metabolic dysfunction-associated steatotic liver disease: From intercellular signaling to clinical translation","volume":"17","author":"Boonkaew","year":"2025","journal-title":"World J. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2025.02.033","article-title":"Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms","volume":"83","author":"Steinberg","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"C1637","DOI":"10.1152\/ajpcell.00951.2024","article-title":"Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease","volume":"328","author":"Kuchay","year":"2025","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Hegazy, M.A., Mohamed, S.S., Saad, E.H., Abdelghani, A., El Fattah, D.A., Mekki, M.A.E., Fathy, M., Hassan, N., and Ashoush, O. (2026). Selenoprotein P deficiency in MASLD: Association with insulin resistance and liver fibrosis\u2014A prospective case-control study. BMC Gastroenterol., 26.","DOI":"10.1186\/s12876-026-04817-2"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Milani, I., Ciasca, G., Chinucci, M., Carnazzo, V., Leonetti, F., Basile, U., and Capoccia, D. (2026). Fetuin-A: A potential molecular link between obesity, diabetes (type 2 and type 1) and metabolic steatotic liver disease (MASLD). J. Endocrinol. Investig., Epub ahead of print.","DOI":"10.1007\/s40618-026-02880-w"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/jgh.16950","article-title":"Irisin alleviates impaired mitochondrial fusion via enhancing PKA\/SIRT3\/mTOR pathway in hepatic steatosis","volume":"40","author":"Li","year":"2025","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA Clinical Practice Update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Friedman","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/hepr.13888","article-title":"Fasting serum fructose is associated with metabolic dysfunction-associated fatty liver disease: A prospective study","volume":"53","author":"Fan","year":"2023","journal-title":"Hepatol. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41575-021-00472-y","article-title":"Dietary carbohydrates and fats in nonalcoholic fatty liver disease","volume":"18","author":"Luukkonen","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1210\/jc.2019-00160","article-title":"Overeating saturated fat promotes fatty liver and ceramides compared with polyunsaturated fat: A randomized trial","volume":"104","author":"Rosqvist","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.2337\/dc18-0071","article-title":"Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars","volume":"41","author":"Luukkonen","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e70303","DOI":"10.1111\/1750-3841.70303","article-title":"Ultra-processed food intake and risk of adverse liver outcomes: A meta-analysis","volume":"90","author":"Guo","year":"2025","journal-title":"J. Food Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.tjnut.2025.04.034","article-title":"Metabolomic and proteomic signatures of ultra-processed foods are positively associated with adverse liver outcomes","volume":"155","author":"Zhao","year":"2025","journal-title":"J. Nutr."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jgh.15363","article-title":"Relationship between dietary patterns and non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"36","author":"Mansoori","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Shang","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_108","first-page":"789","article-title":"The impact of body weight change on liver histology in metabolic dysfunction-associated steatotic liver disease across various histological endpoints: A systematic review and meta-analysis","volume":"121","author":"Jayabalan","year":"2026","journal-title":"Am. J. Gastroenterol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","article-title":"Fructose and sugar: A major mediator of non-alcoholic fatty liver disease","volume":"68","author":"Jensen","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"950","DOI":"10.14309\/ajg.0000000000003379","article-title":"ACG Clinical Guideline: Malnutrition and nutritional recommendations in liver disease","volume":"120","author":"Singal","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.cmet.2026.01.021","article-title":"Targeting microbiota-generated acetaldehyde to prevent progression of metabolic dysfunction-associated steatotic liver disease","volume":"38","author":"Tang","year":"2026","journal-title":"Cell Metab."},{"key":"ref_112","unstructured":"American Diabetes Association Professional Practice Committee (2026). 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes\u20142026. Diabetes Care, 49, S61\u2013S88."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e1900942","DOI":"10.1002\/mnfr.201900942","article-title":"Mitochondrial dysfunction is a key pathway that links saturated fat intake to the development and progression of NAFLD","volume":"65","author":"Meex","year":"2021","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1210\/clinem\/dgae028","article-title":"Lipidomic analysis reveals alterations in hepatic FA profile associated with MASLD stage in patients with obesity","volume":"109","author":"Sledzinski","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e2502978122","DOI":"10.1073\/pnas.2502978122","article-title":"Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis","volume":"122","author":"Sakuma","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/1440-1681.13750","article-title":"Omega-3 polyunsaturated fatty acids in the treatment of non-alcoholic fatty liver disease: An umbrella systematic review and meta-analysis","volume":"50","author":"Musazadeh","year":"2023","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"156028","DOI":"10.1016\/j.metabol.2024.156028","article-title":"The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus","volume":"161","author":"Zeng","year":"2024","journal-title":"Metabolism"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJMe2314365","article-title":"Selective agonists of thyroid hormone receptor beta for the treatment of NASH","volume":"390","author":"Cusi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ajcnut.2023.10.014","article-title":"Higher ultra-processed food intake is associated with adverse liver outcomes: A prospective cohort study of UK Biobank participants","volume":"119","author":"Zhao","year":"2024","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1186\/s41043-025-01150-4","article-title":"Ultra-processed food consumption and the risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD): A five-year prospective cohort study in Iranian adults","volume":"44","author":"Emami","year":"2025","journal-title":"J. Health Popul. Nutr."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1053\/j.gastro.2021.11.006","article-title":"Randomized controlled-feeding study of dietary emulsifier carboxymethylcellulose reveals detrimental impacts on the gut microbiota and metabolome","volume":"162","author":"Chassaing","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/gutjnl-2016-313099","article-title":"Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation","volume":"66","author":"Chassaing","year":"2017","journal-title":"Gut"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"114157","DOI":"10.1016\/j.foodres.2024.114157","article-title":"Food additives impair gut microbiota from healthy individuals and IBD patients in a colonic in vitro fermentation model","volume":"182","author":"Gonza","year":"2024","journal-title":"Food Res. Int."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"115768","DOI":"10.1016\/j.fct.2025.115768","article-title":"The potential influence of food additives and contaminants on the gut microbiota: A comprehensive review","volume":"206","author":"Ullah","year":"2025","journal-title":"Food Chem. Toxicol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/jgh.70259","article-title":"Mediterranean diet adherence is associated with reduced liver fibrosis risk in metabolic dysfunction-associated steatotic liver disease","volume":"41","author":"Hsieh","year":"2026","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(26)00138-8","article-title":"Implementing sustainable liver health in Europe: A second EASL-Lancet Commission","volume":"407","author":"Karlsen","year":"2026","journal-title":"Lancet"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/09637486.2016.1214239","article-title":"Mediterranean diet and nonalcoholic fatty liver disease: Molecular mechanisms of protection","volume":"68","author":"Godos","year":"2017","journal-title":"Int. J. Food Sci. Nutr."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/liv.13435","article-title":"The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms","volume":"37","author":"Salomone","year":"2017","journal-title":"Liver Int."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.3748\/wjg.v24.i19.2083","article-title":"Mediterranean diet and nonalcoholic fatty liver disease","volume":"24","author":"Anania","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Miano, N., Scilletta, S., Di Marco, M., Capuccio, S., Marted\u00ec, M., Coppa, M., Tincu, N., Carasi, S., Ippolito, C., and Pistritto, C. (2026). Adherence to the Mediterranean diet and its association with LDL-cholesterol and subendocardial viability ratio in individuals with familial hypercholesterolemia: A cross-sectional study. Nutrients, 18.","DOI":"10.3390\/nu18060919"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Arita, V.A., Cabezas, M.C., Hern\u00e1ndez Vargas, J.A., Trujillo-C\u00e1ceres, S.J., Mendez Pernicone, N., Bridge, L.A., Raeisi-Dehkordi, H., Dietvorst, C.A.W., Dekker, R., and Uriza-Pinz\u00f3n, J.P. (2025). Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis of randomized controlled trials. BMC Med., 23.","DOI":"10.1186\/s12916-025-04320-7"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0007114526107351","article-title":"Association between the Mediterranean dietary pattern and metabolic dysfunction-associated steatotic liver disease: A longitudinal analysis from UK Biobank","volume":"135","author":"George","year":"2026","journal-title":"Br. J. Nutr."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6621644","DOI":"10.1155\/2021\/6621644","article-title":"Plant-based foods and their bioactive compounds on fatty liver disease: Effects, mechanisms, and clinical application","volume":"2021","author":"Li","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_134","first-page":"CD015033","article-title":"Vitamin E for people with non-alcoholic fatty liver disease","volume":"10","author":"Wen","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1111\/jgh.16723","article-title":"Vitamin E improves serum markers and histology in adults with metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis","volume":"39","author":"Chee","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1080\/10408398.2025.2556470","article-title":"Targeting the gut-liver axis with dietary polyphenols to ameliorate metabolic dysfunction-associated steatotic liver disease: Advances in molecular mechanisms","volume":"66","author":"Hu","year":"2026","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Yang, K., Chen, J., Zhang, T., Yuan, X., Ge, A., Wang, S., Xu, H., Zeng, L., and Ge, J. (2022). Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.949746"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"9233650","DOI":"10.1155\/2022\/9233650","article-title":"A molecular insight into the role of antioxidants in nonalcoholic fatty liver diseases","volume":"2022","author":"Ezhilarasan","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"311","DOI":"10.14309\/ajg.0000000000001584","article-title":"Objectively measured physical activity is inversely associated with nonalcoholic fatty liver disease: The Rotterdam Study","volume":"117","author":"Hofman","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/apt.16631","article-title":"Dose-response relationships of accelerometer-measured sedentary behaviour and physical activity with non-alcoholic fatty liver disease","volume":"54","author":"Tsunoda","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"153588","DOI":"10.1016\/j.bbrc.2026.153588","article-title":"Sleep deprivation exacerbates hepatic steatosis by promoting hepatic inflammation and oxidative stress through gut microbiota dysbiosis in metabolic dysfunction-associated fatty liver disease rat","volume":"813","author":"Hui","year":"2026","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Chen, Y.J., Yang, B.W., Gu, Z.C., and Han, J. (2026). Interplay between circadian rhythms, gut microbiota, and MASLD: From mechanistic foundations to therapeutic opportunities. Front. Med., 13.","DOI":"10.3389\/fmed.2026.1767462"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"10405","DOI":"10.1038\/s41598-025-95336-9","article-title":"Multidimensional sleep impairment predicts steatotic liver disease spectrum risk","volume":"15","author":"Wang","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"113115","DOI":"10.3748\/wjg.v31.i45.113115","article-title":"Revisiting the association between metabolic dysfunction-associated steatotic liver disease and sleep: Moving from correlation to causation","volume":"31","author":"Yao","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1210\/clinem\/dgaf593","article-title":"Diurnal light exposure and rest-activity rhythms in relation to MASLD: Insights from 2 nationwide cohort studies","volume":"111","author":"Wu","year":"2026","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Nieva-Ram\u00edrez, D.G., Uribe, M., and Nu\u00f1o-L\u00e1mbarri, N. (2025). Artificial light at night, sleep disruption, and liver health: Implications for MASLD pathogenesis. Int. J. Environ. Res. Public Health, 22.","DOI":"10.3390\/ijerph22111729"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41575-024-00959-4","article-title":"Food inequity and insecurity and MASLD: Burden, challenges, and interventions","volume":"21","author":"Carrieri","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.14309\/ajg.0000000000002749","article-title":"Food insecurity, low household income, and low education level increase the risk of having metabolic dysfunction-associated fatty liver disease among adolescents in the United States","volume":"119","author":"Paik","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.1038\/s41598-025-93082-6","article-title":"Physical activity, diet, and social determinants of health associate with health related quality of life and fibrosis in MASLD","volume":"15","author":"Czapla","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/jamainternmed.2025.4769","article-title":"Targeting MASLD and MASH in the US Hispanic\/Latino population: A review","volume":"185","author":"Cumpian","year":"2025","journal-title":"JAMA Intern. Med."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Shea, S., Lionis, C., Kite, C., Lagojda, L., Uthman, O.A., Dallaway, A., Atkinson, L., Chaggar, S.S., Randeva, H.S., and Kyrou, I. (2024). Non-alcoholic fatty liver disease and coexisting depression, anxiety and\/or stress in adults: A systematic review and meta-analysis. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1357664"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1097\/HEP.0000000000001368","article-title":"AASLD Practice Statement on the evaluation and management of metabolic dysfunction\u2013associated steatotic liver disease in children","volume":"82","author":"Xanthakos","year":"2025","journal-title":"Hepatology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"119513","DOI":"10.1016\/j.ecoenv.2025.119513","article-title":"The nexus of environmental endocrine-disrupting chemical exposure and metabolic dysfunction-associated steatotic liver disease: An emerging public health challenge","volume":"309","author":"Chen","year":"2026","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"121186","DOI":"10.1016\/j.envres.2025.121186","article-title":"Association between phthalate exposure and metabolic dysfunction-associated steatotic liver disease (MASLD)\u2014Systematic literature review","volume":"273","author":"Gogola","year":"2025","journal-title":"Environ. Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"127985","DOI":"10.1016\/j.envpol.2026.127985","article-title":"Serum polychlorinated biphenyls and risk of metabolic dysfunction-associated steatotic liver disease: Cross-sectional and prospective analyses from the Dongfeng-Tongji cohort","volume":"397","author":"You","year":"2026","journal-title":"Environ. Pollut."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2024.09.033","article-title":"Association of metabolic signatures of air pollution with MASLD: Observational and Mendelian randomization study","volume":"82","author":"Ran","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_157","first-page":"701","article-title":"Updated global consensus recommendations for risk stratification, treatment initiation, and response monitoring in metabolic dysfunction-associated steatotic liver disease","volume":"24","author":"Younossi","year":"2026","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/apt.70433","article-title":"Inherited genetic risk of liver fibrosis in lean versus nonlean metabolic dysfunction\u2013associated steatotic liver disease (MASLD)","volume":"63","author":"Tesfai","year":"2026","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2025.04.035","article-title":"High inherited risk predicts age-associated increases in fibrosis in patients with MASLD","volume":"83","author":"Alazawi","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e3866","DOI":"10.1210\/clinem\/dgaf111","article-title":"Machine learning-based biomarker identification for early diagnosis of metabolic dysfunction-associated steatotic liver disease","volume":"110","author":"Boullion","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"111619","DOI":"10.1016\/j.compbiomed.2026.111619","article-title":"Artificial intelligence for metabolic dysfunction-associated steatotic liver disease diagnosis: A systematic review","volume":"208","author":"Wang","year":"2026","journal-title":"Comput. Biol. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/MED.0000000000000935","article-title":"Emerging concepts in the diagnosis and management of metabolically associated steatotic liver disease","volume":"32","author":"Das","year":"2025","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1001\/jama.2025.26689","article-title":"What is metabolic dysfunction\u2013associated steatotic liver disease?","volume":"335","author":"Voelker","year":"2026","journal-title":"JAMA"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Bakhshimoghaddam, F., Baez, D., Dolatkhah, N., Sheikh, M., Poustchi, H., Hekmatdoost, A., Dawsey, S., Kamangar, F., Abnet, C., and Malekzadeh, R. (2024). Which dietary patterns fend off nonalcoholic fatty liver disease? A systematic review of observational and interventional studies. BMC Nutr., 10.","DOI":"10.1186\/s40795-024-00961-8"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Capuccio, S., Scilletta, S., La Rocca, F., Miano, N., Di Marco, M., Bosco, G., Di Giacomo Barbagallo, F., Scicali, R., Piro, S., and Di Pino, A. (2024). Implications of GLP-1 receptor agonist on thyroid function: A literature review of its effects on thyroid volume, risk of cancer, functionality and TSH levels. Biomolecules, 14.","DOI":"10.3390\/biom14060687"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.eprac.2026.01.006","article-title":"American Association of Clinical Endocrinology Consensus Statement: Algorithm for management of adults with type 2 diabetes\u20142026 update","volume":"32","author":"Samson","year":"2026","journal-title":"Endocr. Pract."},{"key":"ref_168","first-page":"133","article-title":"Recent data from the ESSENCE trial on semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"21","author":"Alkhouri","year":"2025","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.2337\/dc25-1306","article-title":"Relationship between metabolic and histological responses in people with metabolic dysfunction-associated steatohepatitis with and without type 2 diabetes: Participant-level exploratory analysis of the SYNERGY-NASH trial with tirzepatide","volume":"48","author":"Caussy","year":"2025","journal-title":"Diabetes Care"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e186425","DOI":"10.1172\/JCI186425","article-title":"Therapeutic horizons in metabolic dysfunction-associated steatohepatitis","volume":"135","author":"Newsome","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_172","first-page":"877","article-title":"Effectiveness of sodium-glucose cotransporter 2 inhibitors in patients with metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Chen","year":"2026","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e71687","DOI":"10.1096\/fj.202503607RR","article-title":"The gut-liver axis in metabolic dysfunction-associated steatotic liver disease: From mechanistic insights to precision therapeutics","volume":"40","author":"Zhu","year":"2026","journal-title":"FASEB J."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S2468-1253(25)00300-0","article-title":"Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A global Delphi study","volume":"11","author":"Lazarus","year":"2026","journal-title":"Lancet Gastroenterol. Hepatol."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/14\/2316\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:10:02Z","timestamp":1784164202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/14\/2316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":174,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["nu18142316"],"URL":"https:\/\/doi.org\/10.3390\/nu18142316","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}